Johnson & Johnson posts strong revenue in first quarter

Wednesday, April 17, 2019

Print this page Email A Friend!

NEW YORK – USA (AP) —Lower sales overseas and higher costs for research and litigation pushed Johnson &; Johnson's first-quarter profit down 14%. Still, the health care giant beat profit and revenue expectations, pushing up its shares in pre-market trading.

The maker of Tylenol and psoriasis drug Stelara yesterday said unfavourable currency exchange rates reduced revenue by nearly 4%, leaving total sales flat at US$20.03 billion, though that edged out analysts' muted projections.

Sales of prescription medicines were the bright spot as usual, rising 4% and accounting for over half of the New Brunswick, New Jersey, company's total revenue.

The segment just got a boost from two US Food and Drug Administration approvals, in March for nasal spray treatment Spravato for adults with treatment-resistant depression and last week for bladder cancer drug Balversa.

Earlier this month, J&J completed a key acquisition, paying US$3.4 billion for Auris Health, which makes robotic technology used in lung treatments and diagnostic procedures. Johnson & Johnson said the deal will expand its digital surgery portfolio across multiple surgical specialties. J&J also struck a partnership with MeiraGTx to develop gene therapies for eye diseases.

The world's biggest maker of health care products posted net income of US$3.75 billion, or US$1.39 per share, down from US$4.37 billion, or US$1.60 per share, a year earlier.

Earnings, adjusted for litigation costs and research and development expenses, were US$5.66 billion, or US$2.10 per share, seven cents better that Wall Street expected, according to a survey by Zacks Investment Research.

Revenue was US$20.02 billion, with US$10.24 billion of that coming from its prescription drugs. Sales were led by Stelara, which saw a 32.4% jump to US$1.41 billion. Higher sales of cancer drugs Imbruvica and Darzalex, HIV drug Prezista and schizophrenia treatment Invega Sustenna also lifted the results and helped offset lower sales of blockbuster immune treatment Remicade and blood thinner Xarelto.

Sales of consumer health products dipped 2.4% to US$3.32 billion, and medical device sales fell 4.6% to US$6.46 billion.

The company reaffirmed its January forecast for 2019 sales totalling US$80.4 billion to $81.2 billion, but raised the low end of its earnings-per-share forecast three cents, giving a new range of US$8.53 to US$8.63 for the full year.

In premarket trading, J & J shares jumped US$2.57, or 1.9%, to US$139.09.

Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at




1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed:

6. If readers wish to report offensive comments, suggest a correction or share a story then please email:

7. Lastly, read our Terms and Conditions and Privacy Policy

comments powered by Disqus



Today's Cartoon

Click image to view full size editorial cartoon